IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stefan Golz, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2004/010384

Title: Diagnostics and Therapeutics for Diseases Associated with G-Protein

Coupled Receptor ADIPOR1 (ADIPOR1)

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO].

A copy of the International Search Report prepared by the European Patent Office is also enclosed under 37 CFR 1.492(b)(3).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Pellegrino Reg. No.: 48,972

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-6450

Facsimile: (203) 812-6459

10/572883 IAPO Rec'd PCT/PTO 20 MAR 2005

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| Substitute | for form 1449/PT(| 0 | | Complete if Known | | |
|-----------------------------------|-------------------|--------|---------|------------------------|------------------|--|
| | | | | Application Number | [to be assigned] | |
| INIEC | DMATIO | M DISC | LOSURE | Filing Date | <u> </u> | |
| | | | | First Named Inventor | Stefan Golz | |
| STA | TEMENT | BY API | PLICANT | Art Unit | | |
| (Use as many sheets as necessary) | | | | Examiner Name | | |
| neet | 1 | of | 2 | Attorney Docket Number | Le A 36 901 | |

| U. S. PATENT DOCUMENTS | | | | | | | | |
|------------------------|--------------|---|--------------------------------|--|--|--|--|--|
| Examiner Initials* | Cite No.1 | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant | | | |
| | | Number-Kind Code ^{2 (# known)} | - | | Figures Appear | | | |
| | | US- | 1 | | | | | |
| | ļ - | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | <u> </u> | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | | ÚS- | | | | | | |
| _ | | US- | 1 | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--------------------------|--|------------------|--|---|---|--|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages | | | |
| | | Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (# known) | MM-DD-YYYY | | Or Relevant Figures Appear | 1 | | |
| | F1 | WO 03/023008 A2 | 03/20/2003 | Curagen Corporation | | | | |
| | | | | | | | | |
| | | | | | | _ | | |
| | | | | | | L | | |
| | | | | | | | | |
| | | | | | | 1 | | |

| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|
| - | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/572883 IAP9 Rec'd PCT/PTO 20 MAR 2005

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | for form 1449/PTO | | | are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known | | | |
|------------------------|-------------------|-----------|-----------|--|------------------|--|--|
| | | | | Application Number | [to be assigned] | | |
| INFO | RMATION | N DIS | CLOSURE | Filing Date | | | |
| STATEMENT BY APPLICANT | | | PPLICANT | First Named Inventor | Stefan GOLZ | | |
| | 44 | | | Art Unit | | | |
| | (Use as many sh | eets as n | ecessary) | Examiner Name | | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | Le A 36 901 | | |

| | NON PATENT LITERATURE DOCUMENTS | | | | | |
|--------------------------|--|---|--|--|--|--|
| Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published. | | | | | |
| R1 | Yamauchi, T., et al., "Cloning of Adiponectin Receptors that Mediate Antidiabetic Metabolic Effects", Nature, 423: 762-769 (June 2003) | | | | | |
| R2 | Tietge, U. J. F., et al., "Elevated circulating adinopenctin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics", Am. J. Physiol. Endrocrinol. Metab, 287(1): E82-E89 (July 2004) | | | | | |
| R3 | Xu, A., et al., "The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice", J. Clin. Investigation, 112(1): 91-100 (July 2003) | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| - | | - | | | | |
| | No.1 R1 R2 | Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Yamauchi, T., et al., "Cloning of Adiponectin Receptors that Mediate Antidiabetic Metabolic Effects", Nature, 423: 762-769 (June 2003) Tietge, U. J. F., et al., "Elevated circulating adinopenctin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics", Am. J. Physiol. Endrocrinol. Metab, 287(1): E82-E89 (July 2004) Xu, A., et al., "The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice", J. Clin. Investigation, 112(1): 91-100 (July | | | | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: